Poor
Not Aligned
Patient Risk:
Moderate
Summary
Many specific symptom/side-effect and switching-specific claims are not supported by the provided FDA label excerpts; several statements about management phrasing ('often', 'commonly', 'urgent care', switching-specific scenarios) are not directly substantiated. Only partial support exists for muscle-related warnings/monitoring and liver function testing recommendations.
Category Scores
Accurate Statements
Some medicines (e.g., cyclosporine and strong CYP3A4 inhibitors such as clarithromycin, itraconazole, and HIV protease inhibitors) increase the risk of myopathy/rhabdomyolysis with atorvastatin.
Skeletal Muscle (5.1); Drug Interactions (7); Table 1
Patients should be advised to report unexplained muscle pain, tenderness, or weakness promptly.
Skeletal Muscle (5.1)
Liver function tests should be performed prior to therapy and at 12 weeks following initiation and any elevation in dose, and periodically thereafter (e.g., semiannually); patients with increased transaminases should be monitored until abnormalities resolve.
Liver Dysfunction (5.2); Liver Enzymes (17.2)
Unsupported Statements
Generic and brand-name atorvastatin are required to have the same active ingredient.
Not supported by the provided label excerpts.
The side-effect profile of approved generic atorvastatin is expected to be the same as brand-name Lipitor.
Not supported by the provided label excerpts.
Common side effects reported with atorvastatin class drugs include stomach or digestive symptoms such as nausea or diarrhea.
No digestive symptom adverse reaction support in the provided label excerpts.
Headache is a side effect reported with atorvastatin class drugs.
No headache adverse reaction support in the provided label excerpts.
Signs of liver problems associated with statins include unusual fatigue, loss of appetite, upper abdominal pain, dark urine, or yellowing of the skin/eyes.
No such symptom list is supported in the provided label excerpts.
Allergic reactions such as rash, swelling, or trouble breathing may occur with statins.
Hypersensitivity is referenced, but the specific symptom examples are not supported by the provided excerpts.
Switching from brand-name to generic atorvastatin typically should not change the underlying risk because the drug is the same.
Not addressed in the provided label excerpts.
In practice, people may report differences in side effects after switching because of timing of dose changes.
Not addressed in the provided label excerpts.
In practice, people may report differences in side effects after switching because of drug interactions with new medications.
Not addressed in the provided label excerpts in the context of switching.
In practice, people may report differences in side effects after switching due to individual sensitivity and coincidence.
Not addressed in the provided label excerpts.
If muscle pain is mild on generic Lipitor, contacting the prescriber before stopping on your own is recommended.
No label excerpt supports the specific 'mild' threshold or the directive 'before stopping on your own.'
Severe muscle pain with weakness or dark urine warrants urgent care for possible statin-associated muscle injury.
'Urgent care' is not stated in the provided label excerpts.
Clinicians often manage statin side effects by confirming the right dose and adherence.
No such management phrasing or adherence guidance is supported by the provided label excerpts.
Some medicines can raise atorvastatin levels and increase the risk of muscle injury or other adverse effects.
The myopathy/rhabdomyolysis risk with specific interacting agents is supported, but 'other adverse effects' is not supported by the provided excerpts.
Starting new medications including antibiotics, antifungals, HIV medicines, or certain heart or blood pressure drugs may change atorvastatin risk.
Only specific interacting agents/classes (e.g., cyclosporine; strong CYP3A4 inhibitors such as clarithromycin, itraconazole, and certain HIV protease inhibitors) are supported in the provided excerpts; broader categories are not.
Clinicians may consider a different statin or dose strategy if symptoms persist.
The provided excerpts support discontinuation/withholding and dose reduction, but do not specifically support switching to a 'different statin' for persistent symptoms.
Contradictions
Important Omissions
For suspected myopathy: label-specific instruction to discontinue LIPITOR when markedly elevated CPK levels occur or myopathy is diagnosed or suspected (and to temporarily withhold/discontinue in acute serious conditions suggestive of myopathy).
Importance:
Moderate
Label-based contraindication information (e.g., active liver disease or unexplained persistent transaminase elevations are contraindications) is not reflected in any of the evaluated claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported/overreaching symptom and switching-related claims (e.g., digestive symptoms, headache, specific liver symptom set, allergic reaction examples, switching scenarios, 'urgent care') could misinform recognition/response. Core labeled safety elements for muscle reporting, drug interaction risk for myopathy, and liver enzyme monitoring are only partially and indirectly addressed.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Not Aligned
Primary Issue
Multiple claims about side effects (e.g., nausea/diarrhea, headache, specific liver symptom constellation, allergy symptom examples) and switching-specific expectations are not supported by the provided FDA label excerpts.
Suggested Improvement
Restrict statements to label-supported content: (1) myopathy warning to report unexplained muscle pain/tenderness/weakness and discontinue when suspected/diagnosed with markedly elevated CPK; (2) interaction risk with specific listed agents; (3) liver function test timing and monitoring/management thresholds as described; remove or qualify unsupported symptom lists and switching-specific 'in practice' assertions.